Search

Your search keyword '"Ribera, Esteban"' showing total 493 results
Start Over Author "Ribera, Esteban"
493 results on '"Ribera, Esteban"'

4. Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018)

Author

Pérez-Molina, José A., Polo, Rosa, López-Aldeguer, José, Lozano, Fernando, Aguirrebengoa, Koldo, Arribas, José Ramón, Boix, Vicente, Berenguer, Juan, Blanco, José Ramón, Domingo, Pere, Estrada, Vicente, Galindo, María José, García, Federico, Gatell, José María, González-García, Juan, Gutiérrez, Félix, Iribarren, José Antonio, Knobel, Hernando, Llibre, Josep María, López-Bernaldo de Quirós, Juan Carlos, López-Cortés, Luis Fernando, Losa, Juan Emilio, Mariño, Ana, Miró, José M., Montes, María L., Moreno, Santiago, Negredo, Eugenia, Pérez-Elías, María J., Podzamczer, Daniel, Portilla, Joaquín, Poveda, Eva, Pulido, Federico, Ribera, Esteban, Rivero, Antonio, Rubio, Rafael, Santos, Jesús, Sanz-Moreno, José, Sanz-Sanz, Jesús, Serrano, Sergio, de la Torre, Javier, Tuset, Montserrat, von Wichman, Miguel A., and Martínez, Esteban

Published
2019
Full Text
View/download PDF

6. Impacto económico asociado a la implementación de las recomendaciones con grado de evidencia A-I del documento de consenso de GeSIDA/PNS (2015) relativas a la optimización del tratamiento antirretroviral en adultos infectados por virus de la inmunodeficiencia humana con carga viral suprimida en España

Author

Ribera, Esteban, Martínez-Sesmero, José Manuel, Sánchez-Rubio, Javier, Rubio, Rafael, Pasquau, Juan, Poveda, José Luis, Pérez-Mitru, Alejandro, Roldán, Celia, and Hernández-Novoa, Beatriz

Published
2018
Full Text
View/download PDF

7. Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression : Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial

Author

DUAL-GESIDA-8014-RIS-EST45 Study Group, Pulido, Federico, Ribera, Esteban, Lagarde, María, Pérez-Valero, Ignacio, Palacios, Rosario, Iribarren, José A., Payeras, Antoni, Domingo, Pere, Sanz, José, Cervero, Miguel, Curran, Adrián, Rodríguez-Gómez, Francisco J., Téllez, María J., Ryan, Pablo, Barrufet, Pilar, Knobel, Hernando, Rivero, Antonio, Alejos, Belén, Yllescas, María, and Arribas, José R.

Published
2017

8. Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015

Author

Iribarren, José Antonio, Rubio, Rafael, Aguirrebengoa, Koldo, Arribas, Jose Ramón, Baraia-Etxaburu, Josu, Gutiérrez, Félix, Lopez Bernaldo de Quirós, Juan Carlos, Losa, Juan Emilio, Miró, José M<ce:sup loc='post">a</ce:sup>, Moreno, Santiago, Pérez Molina, José, Podzamczer, Daniel, Pulido, Federico, Riera, Melchor, Rivero, Antonio, Sanz Moreno, José, Amador, Concha, Antela, Antonio, Arazo, Piedad, Arrizabalaga, Julio, Bachiller, Pablo, Barros, Carlos, Berenguer, Juan, Caylá, Joan, Domingo, Pere, Estrada, Vicente, Knobel, Hernando, Locutura, Jaime, López Aldeguer, José, Llibre, Josep M<ce:sup loc='post">a</ce:sup>, Lozano, Fernando, Mallolas, Josep, Malmierca, Eduardo, Miralles, Celia, Miralles, Pilar, Muñoz, Agustín, Ocampo, Agustín, Olalla, Julián, Pérez, Inés, Pérez Elías, M<ce:sup loc='post">a</ce:sup> Jesús, Pérez Arellano, José Luis, Portilla, Joaquín, Ribera, Esteban, Rodríguez, Francisco, Santín, Miguel, Sanz Sanz, Jesús, Téllez, M<ce:sup loc='post">a</ce:sup> Jesús, Torralba, Miguel, Valencia, Eulalia, and Von Wichmann, Miguel Angel

Published
2016
Full Text
View/download PDF

9. Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab

Author

Serra-Peinado, Carla, Grau-Expósito, Judith, Luque-Ballesteros, Laura, Astorga-Gamaza, Antonio, Navarro, Jordi, Gallego-Rodriguez, Jenny, Martin, Mario, Curran, Adrià, Burgos, Joaquin, Ribera, Esteban, Raventós, Berta, Willekens, Rein, Torrella, Ariadna, Planas, Bibiana, Badía, Rosa, Garcia, Felipe, Castellví, Josep, Genescà, Meritxell, Falcó, Vicenç, and Buzon, Maria J.

Published
2019
Full Text
View/download PDF

12. Differential Body Composition Effects of Protease Inhibitors Recommended for Initial Treatment of HIV Infection: A Randomized Clinical Trial

Author

ATADAR Study Group, Martinez, Esteban, Gonzalez-Cordon, Ana, Ferrer, Elena, Domingo, Pere, Negredo, Eugenia, Gutierrez, Felix, Portilla, Joaquin, Curran, Adriá, Podzamczer, Daniel, Ribera, Esteban, Murillas, Javier, Bernardino, Jose I., Santos, Ignacio, Carton, Jose A., Peraire, Joaquim, Pich, Judit, Deulofeu, Ramon, Perez, Ignacio, and Gatell, Jose M.

Published
2015

16. Restoration of T Cell Responses to Toxoplasma gondii after Successful Combined Antiretroviral Therapy in Patients with AIDS with Previous Toxoplasmic Encephalitis

Author

the Spanish Toxoplasma gondii Study Group, Lejeune, Marylène, Miró, José M., De Lazzari, Elisa, García, Felipe, Claramonte, Xavier, Martínez, Esteban, Ribera, Esteban, Arrizabalaga, Julio, Arribas, José R., Domingo, Pere, Ferrer, Elena, Plana, Montserrat, Valls, María-Eugenia, Podzamczer, Daniel, Pumarola, Tomás, Jacquet, Alain, Mallolas, Josep, Gatell, José M., and Gallart, Teresa

Published
2011
Full Text
View/download PDF

18. Didanosine, Lamivudine, and Efavirenz versus Zidovudine, Lamivudine, and Efavirenz for the Initial Treatment of HIV Type 1 Infection: Final Analysis (48 Weeks) of a Prospective, Randomized, Noninferiority Clinical Trial, GESIDA 3903

Author

Berenguer, Juan, González, Juan, Ribera, Esteban, Domingo, Pere, Santos, Jesús, Miralles, Pilar, Ribas, Ma. Angels, Asensi, Víctor, Gimeno, Juan Luis, Pérez-Molina, José Antonio, Terrón, José Alberto, Santamaría, Juan Miguel, and Pedrol, Enric

Published
2008
Full Text
View/download PDF

19. Characteristics and outcome of HIV infection in gypsies in the Spanish VACH Cohort

Author

Teira, Ramón, Suárez-Lozano, Ignacio, Lozano, Fernando, Viciana, Pompeyo, Domingo, Pere, Galindo, Pepa, Geijo, Paloma, Terrón, Alberto, González, Juan, Cosín, Jaime, Ribera, Esteban, Roca, Bernardino, García-Alcalde, María L., Sánchez, Trinitario, Muñoz-Sánchez, Agustín, Vergara, Antonio, López-Aldeguer, José, Pedrol, Enric, Vidal, Francesc, Garrido, Myriam, and Santamaría, Juan M.

Published
2010
Full Text
View/download PDF

21. Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial

Author

Moltó, José, Valle, Marta, Ferrer, Elena, Domingo, Pere, Curran, Adrian, Santos, José Ramón, Mateo, María Gracia, Di Yacovo, María Silvana, Miranda, Cristina, Podzamczer, Daniel, Clotet, Bonaventura, Clotet, Bonaventura, Coll, Josep, Gel, Silvia, Llibre, Josep Maria, Miranda, Cristina, Moltó, José, Mothe, Beatriz, Negredo, Eugenia, Pérez-Álvarez, Nuria, Santos, José Ramón, Sirera, Guillem, DiYacovo, María Silvana, Ferrer, Elena, Podzamczer, Daniel, Rozas, Nerea, Vila, Antonia, Domingo, Pere, Del Mar Gutiérrez, María, Mateo, Gracia, Valle, Marta, Burgos, Joaquín, Curran, Adrian, Navarro, Jordi, and Ribera, Esteban

Published
2015
Full Text
View/download PDF

23. Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015

Author

Iribarren, José Antonio, Rubio, Rafael, Aguirrebengoa, Koldo, Arribas, Jose Ramón, Baraia-Etxaburu, Josu, Gutiérrez, Félix, Lopez Bernaldo de Quirós, Juan Carlos, Losa, Juan Emilio, Miró, José M<ce:sup loc='post">a</ce:sup>, Moreno, Santiago, Pérez Molina, José, Podzamczer, Daniel, Pulido, Federico, Riera, Melchor, Rivero, Antonio, Sanz Moreno, José, Amador, Concha, Antela, Antonio, Arazo, Piedad, Arrizabalaga, Julio, Bachiller, Pablo, Barros, Carlos, Berenguer, Juan, Caylá, Joan, Domingo, Pere, Estrada, Vicente, Knobel, Hernando, Locutura, Jaime, López Aldeguer, José, Llibre, Josep M<ce:sup loc='post">a</ce:sup>, Lozano, Fernando, Mallolas, Josep, Malmierca, Eduardo, Miralles, Celia, Miralles, Pilar, Muñoz, Agustín, Ocampo, Agustín, Olalla, Julián, Pérez, Inés, Pérez Elías, M<ce:sup loc='post">a</ce:sup> Jesús, Pérez Arellano, José Luis, Portilla, Joaquín, Ribera, Esteban, Rodríguez, Francisco, Santín, Miguel, Sanz Sanz, Jesús, Téllez, M<ce:sup loc='post">a</ce:sup> Jesús, Torralba, Miguel, Valencia, Eulalia, and Von Wichmann, Miguel Angel

Published
2016
Full Text
View/download PDF

27. Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review

Author

Palacio Vieira, Jorge, Reyes Urueña, Juliana Maria, Imaz, Arkaitz, Bruguera, Andreu, Force, Lluís, Ortí Llaveria, Amat, Llibre, Josep María, Vilaró, Ingrid, Homar Borràs, Francesc, Falcó, Vicenç, Riera, Melchor, Navarro, G., Cortés, C., Mallolas Masferrer, Josep, Manzardo, Christian, Tiraboschi, Juan Manuel, Curran, Adrian, Burgos, J., Gracia Mateo, María, Gutiérrez, Maria del Mar, Murillas Angoiti, Javier, Segura, F., García Gasalla, M., Gonzalez, E., Vidal, Francesc, Peraire, Joaquim, Leon, E., Masabeu, Àngels, Dalmau, D., Jaén, Angels, Almuedo Riera, Alex, Giralt, D., Raventós, B., Gargoulas, F., Vanrell, T., Rubia, J. C., Vilà, J., Ferrés, M., Morell, B., Tamayo, M., Ambrosioni, J., Laguno, M., Martínez, M., Blanco, J. L., Garcia Alcaide, F., Martínez, E., Jou, A., Clotet i Sala, Bonaventura, Saumoy, Maria, Silva, A., Prieto, P., Navarro Bernabé, Joan, Ribera, Esteban, Gurgui Ferrer, Mercedes, Ribas, Maria Àngels, Campins, Antoni, Fanjul, Francisco, Leyes, M., Peñaranda, María, Martin, L., Vilchez, H., Calzado, S., Cervantes, M., Amengual, M. J., Navarro, M., Payeras, T., Cifuentes, Carmen, Abdulghani, N., Comella, T., Vargas, Montserrat, Viladés, Consuelo, Barrufet, Pilar M., Chivite, Ivan, Chamarro, E., Escrig, C., Cairó, Mireia, Martinez Lacasa, X., Font, R., Meyer, Sebastián, Hernandez, Juanse, Picis Study Group, Domingo, Pere (Domingo Pedrol), Lazzari, Elisa de, Miró, Josep M., Casabona, Jordi, Moreno, Sergio, Diaz, Yesika, Aceiton, Jordi, Muntada, Esteve, Podzamczer Palter, Daniel, Institut Català de la Salut, [Palacio-Vieira J] Centre for Epidemiological Studies on Sexually Transmitted Infections and HIV/AIDS of Catalonia (CEEISCAT), Badalona, Spain. CIBER Epidemiologia y Salud Pública (CIBERESP), Barcelona, Spain. Hospital Clinic-Institut d’Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain. [Reyes-Urueña JM] Centre for Epidemiological Studies on Sexually Transmitted Infections and HIV/AIDS of Catalonia (CEEISCAT), Badalona, Spain. CIBER Epidemiologia y Salud Pública (CIBERESP), Barcelona, Spain. Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain. [Imaz A] HIV and STI Unit, Department of Infectious Diseases, Bellvitge University Hospital-IDIBELL, L’Hospitalet de Llobregat, Spain. [Bruguera A] Centre for Epidemiological Studies on Sexually Transmitted Infections and HIV/AIDS of Catalonia (CEEISCAT), Badalona, Spain. Institute for Health Science Research Germans Trias i Pujol (IGTP), Badalona, Spain. [Force L] Internal Medicine, Hospital de Mataró-Consorci Sanitari del Maresme, Mataró, Spain. [Llaveria AO] Internal Medicine, Hospital Verge de la Cinta de Tortosa, Tortosa, Spain. [Falcó V] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
medicine.medical_specialty, virosis::infecciones por virus ARN::infecciones por Retroviridae::infecciones por Lentivirus::infecciones por VIH [ENFERMEDADES], Scopus, HIV Infections, Lost to follow-up, Investigative Techniques::Epidemiologic Methods::Epidemiologic Research Design::Lost to Follow-Up [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Phone, Patient compliance [LCSH], Humans, Medicine, Virus Diseases::RNA Virus Infections::Retroviridae Infections::Lentivirus Infections::HIV Infections [DISEASES], business.industry, Linkage, Developed Countries, técnicas de investigación::métodos epidemiológicos::diseño de la investigación epidemiológica::pérdidas en el seguimiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Public health, Public Health, Environmental and Occupational Health, HIV, Grey literature, Reengagement, Family medicine, Income, Cohort studies, Infeccions per VIH, Cooperació dels malalts, Public aspects of medicine, RA1-1270, Biostatistics, business, Pacients - Participació, Research Article, Cohort study, HIV infections
Abstract

Estudios de cohortes; VIH; Pérdida de seguimiento Cohort studies; HIV; Lost to follow-up Estudis de cohorts; VIH; Pèrdua del seguiment Background Despite remarkable achievements in antiretroviral therapy (ART), losses to follow-up (LTFU) might prevent the long-term success of HIV treatment and might delay the achievement of the 90–90-90 objectives. This scoping review is aimed at the description and analysis of the strategies used in high-income countries to reengage LTFU in HIV care, their implementation and impact. Methods A scoping review was done following Arksey & O′Malley’s methodological framework and recommendations from Joanna Briggs Institute. Peer reviewed articles were searched for in Pubmed, Scopus and Web of Science; and grey literature was searched for in Google and other sources of information. Documents were charted according to the information presented on LTFU, the reengagement procedures used in HIV units in high-income countries, published during the last 15 years. In addition, bibliographies of chosen articles were reviewed for additional articles. Results Twenty-eight documents were finally included, over 80% of them published in the United States later than 2015. Database searches, phone calls and/or mail contacts were the most common strategies used to locate and track LTFU, while motivational interviews and strengths-based techniques were used most often during reengagement visits. Outcomes like tracing activities efficacy, rates of reengagement and viral load reduction were reported as outcome measures. Conclusions This review shows a recent and growing trend in developing and implementing patient reengagement strategies in HIV care. However, most of these strategies have been implemented in the United States and little information is available for other high-income countries. The procedures used to trace and contact LTFU are similar across reviewed studies, but their impact and sustainability are widely different depending on the country studied. The project leading to these results (PISCIS Cohort) has received funding from “la Caixa” Banking Foundation under the project code LCF/PR/PR17/51120008. This work is supported by a grant from the Foundation Marató TV3 (project code 239/C/2018) aimed at the analysis of the LTFU patients of the PISCIS Cohort. The funding bodies played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Published
2021

28. Real world effectiveness of standard of care triple therapy versus two-drug combinations for treatment of people living with HIV

Author

Universitat Rovira i Virgili, Teira, Ramon; Diaz-Cuervo, Helena; Aragao, Filipa; Marguet, Sophie; de la Fuente, Belen; Jose Munoz, Maria; Abdulghani, Nadia; Ribera, Esteban; Domingo, Pere; Deig, Elisabeth; Peraire, Joaquim; Roca, Bernardino; Montero, Marta; Jose Galindo, Maria; Romero, Alberto; Espinosa, Nuria; Lozano, Fernando; Dolores Merino, Maria; Martinez, Elisa; Geijo, Paloma; Estrada, Vicente; Garcia, Josefina; Antonia Sepulveda, M.; Berenguer, Juan, Universitat Rovira i Virgili, and Teira, Ramon; Diaz-Cuervo, Helena; Aragao, Filipa; Marguet, Sophie; de la Fuente, Belen; Jose Munoz, Maria; Abdulghani, Nadia; Ribera, Esteban; Domingo, Pere; Deig, Elisabeth; Peraire, Joaquim; Roca, Bernardino; Montero, Marta; Jose Galindo, Maria; Romero, Alberto; Espinosa, Nuria; Lozano, Fernando; Dolores Merino, Maria; Martinez, Elisa; Geijo, Paloma; Estrada, Vicente; Garcia, Josefina; Antonia Sepulveda, M.; Berenguer, Juan

Abstract

BackgroundSince 1996, the standard of care (SOC) therapy for HIV treatment has consisted of a backbone of two nucleoside analogue reverse transcriptase inhibitors (NRTI) paired with a third agent. Use of two-drug combinations (2DC) has been considered for selected patients to avoid toxicities associated with the use of NRTIs. This study aimed to compare the real-world outcomes of integrase strand transfer inhibitor (INSTI)-containing triple therapy (TT) to dolutegravir- (DTG) and/or boosted protease inhibitor (bPI)-based 2DC in a large Spanish cohort of HIV patients.MethodsA retrospective analysis was performed using data from the VACH cohort, a prospective multicentre Spanish cohort of adult HIV patients. All treatment experienced patients initiating a TT of an INSTI combined with two NRTIs or a 2DC-containing DTG and/or a bPI between 01/01/2012 and 01/06/2017 were included. The unit of analysis was patient-regimens. The overall sample analysis was complemented with two sub-analyses. The first sub-analysis focused on patients treated with a backbone plus DTG compared to those treated with DTG+ one other antiretroviral. The second sub-analysis focused on patients with HIV RNA<50 copies/mL at baseline, irrespective of the regimen used. The following endpoints were assessed: time to discontinuation for any reason, time to switch due to virologic failure, and time to switch due to toxicity (reasons for discontinuation according to clinician report in the database). Time-to-event analyses were conducted using Kaplan-Meier survival curves and Cox regression models.ResultsOverall 7,481 patients were included in the analysis, contributing to 9,243 patient-regimens. Patient characteristics at baseline differed among groups, with the 2DC group being significantly older and havin

Published
2021

29. Recomendaciones españolas sobre el uso adecuado de enfuvirtida

Author

Ribera, Esteban, Moreno, Santiago, Viciana, Pompeyo, Echevarría, Santiago, Flores, Juan, Francés, Adela, Luis Gómez-Sirvent, Juan, González, Juan, Hernández-Quero, José, Lozano, Fernando, Mallolas, Josep, Muñoz, Agustín, Ocampo, Antonio, Portilla, Joaquín, Pulido, Federico, Rivero, Antonio, Santos, Jesús, Soriano, Vicente, Antela, Antonio, Arazo, Piedad, Ramón Arribas, José, Cervantes, Manel, and Domingo, Pere

Published
2007
Full Text
View/download PDF

30. Discontinuation of primary and secondary toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial

Author

Miro, Jose M., Lopez, Juan C., Podzamczer, Daniel, Pena, Jose M., Alberdi, Juan C., Martinez, Esteban, Domingo, Pere, Cosin, Jaime, Claramonte, Xavier, Arribas, Jose R., Santin, Miguel, and Ribera, Esteban

Subjects
Toxoplasma -- Research, HIV patients -- Care and treatment, HIV patients -- Research, HIV patients -- Physiological aspects, Antiviral agents -- Usage, Clinical trials -- Management, Company business management, Health, Health care industry
Published
2006

31. Real world effectiveness of standard of care triple therapy versus two-drug combinations for treatment of people living with HIV

Author

Teira, Ramón, primary, Diaz-Cuervo, Helena, additional, Aragão, Filipa, additional, Marguet, Sophie, additional, de la Fuente, Belén, additional, Muñoz, Maria Jose, additional, Abdulghani, Nadia, additional, Ribera, Esteban, additional, Domingo, Pere, additional, Deig, Elisabeth, additional, Peraire, Joaquim, additional, Roca, Bernardino, additional, Montero, Marta, additional, Galindo, Maria José, additional, Romero, Alberto, additional, Espinosa, Nuria, additional, Lozano, Fernando, additional, Merino, María Dolores, additional, Martínez, Elisa, additional, Geijo, Paloma, additional, Estrada, Vicente, additional, García, Josefina, additional, Sepúlveda, M. Antonia, additional, and Berenguer, Juan, additional

Published
2021
Full Text
View/download PDF

32. Late presentation for HIV impairs immunological but not virological response to antiretroviral treatment

Author

Rava, Marta, primary, Bisbal, Otilia, additional, Domínguez-Domínguez, Lourdes, additional, Aleman, Ma Remedios, additional, Rivero, María, additional, Antela, Antonio, additional, Estrada, Vicente, additional, Ribera, Esteban, additional, Muñoz, Adolfo, additional, Iribarren, José-Antonio, additional, Moreno, Santiago, additional, Rubio, Rafael, additional, and Jarrín, Inmaculada, additional

Published
2021
Full Text
View/download PDF

33. Failure of cetirizine to prevent nevirapine-associated rash: a double-blind placebo-controlled trial for the GESIDA 26/01 study

Author

Knobel, Hernando, Miro, Jose M., Mahillo, Beatriz, Domingo, Pere, Rivero, Antonia, Ribera, Esteban, Gonzalez, Juan, Gonzalez, Alicia, Blanco, Jose Luis, Boix, Vicente, Force, Luis, Llibre, Josep M., Dalmau, David, Arroyo, Juan A., Torre, Julian De la, Rodriguez, Dolors, Montes, Maria Luisa, Arranz, Alberto, Sarasa, Maria, and Jose, Sanz

Subjects
Cetirizine -- Dosage and administration, Nevirapine -- Diagnosis, Nevirapine -- Risk factors, Experimental design -- Research, Health
Abstract

An attempt was made to evaluate the efficacy of cetirizine in the prevention of nevirapine rash using a double-blind placebo-controlled study. By performing this study, it was concluded that cetirizine does not prevent the incidence or affect the severity of neviropine-associated rash.

Published
2004

34. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection

Author

Martinez, Esteban, Arnaiz, Juan A., Podzamczer, Daniel, Dalmau, David, Ribera, Esteban, Domingo, Pere, Knobel, Hernando, Riera, Melcior, Pedrol, Enric, Force, Lluis, Llibre, Josep M., Segura, Ferran, Richart, Cristobal, Cortes, Cristina, Javaloyas, Manuel, Aranda, Miquel, Cruceta, Ana, Lazzari, Elisa de, and Gatell, Jose M.

Subjects
Abacavir -- Evaluation, HIV infection -- Drug therapy, Nevirapine -- Evaluation
Abstract

Nevirapine and efavirenz may be more effective AIDS drugs than abacavir, according to a study of 460 HIV patients. These drugs are often used instead of protease inhibitors because protease inhibitors have serious side effects. In this study, abacavir seemed to have fewer side effects than the other two drugs.

Published
2003

35. Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. (Major Article: HIV/AIDS)

Author

Berenguer, Juan, Miralles, Pilar, Arrizabalaga, Julio, Ribera, Esteban, Dronda, Fernando, Baraia-Etxaburu, Josu, Domingo, Pere, Marquez, Manuel, Rodriguez-Arrond, Francisco J., Laguna, Fernando, Rubio, Rafael, Rodrigo, Jose Lacruz, Mallolas, J., and Miguel, Veronica de

Subjects
Communicable diseases -- Research, Leukoencephalopathy, Progressive multifocal -- Physiological aspects, Leukoencephalopathy, Progressive multifocal -- Patient outcomes, Highly active antiretroviral therapy -- Physiological aspects, Highly active antiretroviral therapy -- Research, AIDS (Disease) -- Physiological aspects, AIDS (Disease) -- Drug therapy, AIDS (Disease) -- Patient outcomes, Health, Health care industry
Published
2003

36. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: Report of 12 cases and review of the literature. (HIV/AIDS)

Author

Falco, Vicente, Rodriguez, Dolors, Ribera, Esteban, Martinez, Esteban, Miro, Jose Maria, Domingo, Pere, Diazaraque, Ruth, Arribas, Jose R., Gonzalez-Garcia, Juan J., Montero, Francesc, Sanchez, Lluis, and Pahissa, Albert

Subjects
Lactic acidosis -- Care and treatment, HIV infection -- Complications, Anti-HIV agents -- Adverse and side effects, Health, Health care industry
Published
2002

38. Switching to Raltegravir in Virologically Suppressed in HIV-1-Infected Patients: A Retrospective, Multicenter, Descriptive Study§

Author

Podzamczer, Daniel, Martínez, Esteban, Domingo, Pere, Ferrer, Elena, Viciana, Pompeyo, Curto, Jordi, Pérez-Elías, Maria-Jesús, Ocampo, Antonio, Santos, Ignacio, Knobel, Hernando, Estrada, Vicente, Negredo, Eugenia, Segura, Ferrán, Portilla, Joaquín, Ribera, Esteban, Galindo, Josefa, Antela, Antonio, Carmena, Jorge, and Castaño, Manuel

Published
2012

39. Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis

Author

Ribera, Esteban, Pou, Leonor, Lopez, Rosa M., Crespo, Manuel, Falco, Vicenc, Ocana, Imma, Ruiz, Isabel, and Pahissa, Albert

Subjects
AIDS (Disease) -- Drug therapy, HIV infection -- Physiological aspects, Nevirapine -- Evaluation, Rifampin -- Evaluation, Tuberculosis -- Drug therapy, Drug interactions -- Research, Health
Abstract

Study has shown that rifampicin reduces serum exposure to nevirapine, but clinical implications are yet to be established. Pharmacokinetic interaction between nevirapine and rifampicin has been studied in HIV-infected patients with tuberculosis. The steady-state serum pharmacokinetics (PKs) of nevirapine before and during treatment with rifampicin and the steady-state serum PKs of rifampicin in patients receiving rifampicin alone or in combination with nevirapine are reported.

Published
2001

40. A randomized trial of hte discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection

Author

Lopez Bernaldo de Quiros, Juan C., Miro, Jose M., Pena, Jose M., Podzamczer, Daniel, Alberdi, Juan C., Martinez, Esteban, Cosin, Jaime, Claramonte, Xavier, Gonzalez, Juan, Domingo, Pere, Casado, Jose L., and Ribera, Esteban

Subjects
HIV infection -- Drug therapy, Pneumocystis carinii pneumonia -- Prevention
Abstract

HIV patients whose CD4 T cell counts increase to 200 or more as a result of antiretroviral therapy can stop taking drugs to prevent Pneumocystis carinii pneumonia (PCP). In a study of 714 such patients, none of the 300 patients who stopped taking drugs to prevent PCP developed PCP during a one- to two-year follow-up.

Published
2001

42. Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals

Author

Imaz, Arkaitz, Llibre, Josep M., Mora, Marta, Mateo, Gracia, Camacho, Angela, Blanco, José R., Curran, Adrian, Santos, José R., Caballero, Estrella, Bravo, Isabel, Gayá, Francisco, Domingo, Pere, Rivero, Antonio, Falcó, Vicenç, Clotet, Bonaventura, and Ribera, Esteban

Published
2011
Full Text
View/download PDF

43. Screening for asymptomatic STIs in HIV-infected men who have sex with men

Author

Willekens, Rein, primary, Sánchez, Irene, additional, Miguel, Lucía, additional, Esperalba, Juliana, additional, Serra-Pladevall, Judit, additional, Martin, Mario, additional, Navarro, Jordi, additional, Falcó, Vicenç, additional, Burgos, Joaquín, additional, Ribera, Esteban, additional, Caballero, Estrella, additional, and Curran, Adrian, additional

Published
2020
Full Text
View/download PDF

44. Lipidomics Reveals Reduced Inflammatory Lipid Species and Storage Lipids after Switching from EFV/FTC/TDF to RPV/FTC/TDF: A Randomized Open-Label Trial

Author

Curran, Adrian, primary, Rull, Anna, additional, Navarro, Jordi, additional, Vidal-González, Judit, additional, Martin-Castillo, Mario, additional, Burgos, Joaquin, additional, Falcó, Vicenç, additional, Ribera, Esteban, additional, Torrella, Ariadna, additional, Planas, Bibiana, additional, Peraire, Joaquim, additional, and Crespo, Manuel, additional

Published
2020
Full Text
View/download PDF

45. Effectiveness of boosted darunavir plus rilpivirine in patients with long-lasting HIV-1 infection: DARIL study

Author

Navarro, Jordi, primary, González-Cordón, Ana, primary, Casado, José Luís, primary, Bernardino, Jose I, primary, Domingo, Pere, primary, Portilla, Joaquin, primary, Llibre, Josep Maria, primary, Colomer, Joan, primary, Rial-Crestelo, David, primary, Vizcarra, Pilar, primary, Curran, Adrià, primary, Martínez, Esteban, primary, and Ribera, Esteban, primary

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results